BioElectronics Corporation (BIEL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioElectronics Corporation (BIEL) trades at $0.00 with AI Score 53/100 (Grade B). BioElectronics Corporation specializes in developing and selling wearable neuromodulation devices globally, addressing neurological diseases and enhancing quality of life. Market cap: $6.33M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BIEL: BIEL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIEL against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BIEL: 2/6 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →BioElectronics Corporation (BIEL) Healthcare & Pipeline Overview
BioElectronics Corporation is an electroceutical company focused on developing and commercializing wearable neuromodulation devices for pain management and quality of life improvement. Its product line targets human applications like musculoskeletal and menstrual pain, as well as veterinary uses, distributing to wholesale, clinical, and consumer channels globally.
What Is the Investment Thesis for BIEL?
BioElectronics Corporation (BIEL) operates in the specialized and growing electroceutical market, focusing on wearable neuromodulation devices for pain management. The company's diverse product line, including ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast, addresses both human and animal health, providing multiple avenues for revenue generation. With a gross margin of 73.3%, the company demonstrates strong product-level profitability, indicating efficient cost management for its core offerings. While the current profit margin stands at -187.6% and the market capitalization is $0.01B, suggesting early-stage or re-investment heavy operations, the high gross margin provides a foundation for future profitability if sales volume and operational efficiency scale. The beta of 2.07 indicates higher volatility compared to the broader market, which could appeal to investors seeking higher risk-reward profiles. Future growth catalysts include potential expansion into new therapeutic areas, increased adoption in professional medical settings, and broader international distribution, leveraging its existing product efficacy.
Based on FMP financials and quantitative analysis
BIEL Key Highlights
- Market Capitalization of $6.33M, reflecting its current valuation as a micro-cap company.
- Gross Margin of 73.3%, indicating strong profitability on its core product sales before operating expenses.
- Profit Margin of -187.6%, highlighting significant operational losses relative to revenue, likely due to investment in R&D or sales infrastructure.
- Beta of 2.07, suggesting the stock's price is significantly more volatile than the overall market.
- A lean operational structure with 9 employees, indicating a focused and potentially agile organization.
Who Are BIEL's Competitors?
BIEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIEL's Key Strengths?
- Specialized focus on electroceutical wearable neuromodulation devices.
- Diverse product portfolio addressing both human and animal health applications.
- Strong gross margin of 73.3% on product sales.
- Established distribution channels including wholesale, medical, and direct-to-consumer.
What Are BIEL's Weaknesses?
- Negative profit margin of -187.6% indicating significant operational losses.
- Small employee base of 9, potentially limiting scalability and R&D capacity.
- Market capitalization of $6.33M, reflecting a micro-cap status with potential liquidity challenges.
- High beta of 2.07 suggests significant stock price volatility.
What Could Drive BIEL Stock Higher?
- Successful launch of new neuromodulation devices for additional therapeutic indications, expanding market reach beyond current offerings.
- Increased adoption of RecoveryRx in professional medical settings, driven by positive clinical outcomes and expanded sales efforts.
- Expansion of distribution channels and market penetration for HealFast in the growing animal health sector.
- Strategic partnerships or collaborations to accelerate market entry into new international geographies or enhance product development capabilities.
What Are the Key Risks for BIEL?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Continued negative profit margins could deplete capital and hinder future growth initiatives.
- Intense competition in the medical device and pain management markets from larger, more established players.
- Regulatory challenges or delays in obtaining approvals for new products or market expansions.
- Dependence on consumer and medical professional acceptance of electroceutical therapies as alternatives to traditional treatments.
- Limited financial disclosure and low liquidity due to OTC Other tier listing, posing risks for investors.
What Are the Growth Opportunities for BIEL?
- **Expansion into New Therapeutic Areas:** BioElectronics Corporation has established a platform with its neuromodulation technology. A significant growth opportunity lies in leveraging this core technology to develop new wearable devices targeting additional neurological conditions or pain indications beyond its current offerings. This could involve conditions like neuropathic pain, migraines, or specific chronic pain syndromes, expanding the total addressable market. The market for chronic pain management devices is substantial, with global estimates often exceeding tens of billions of dollars annually, presenting a long-term growth trajectory for specialized solutions.
- **Increased Penetration in Professional Medical Settings:** The RecoveryRx device is specifically marketed to medical professionals. A key growth driver involves intensifying sales and marketing efforts to increase adoption within hospitals, clinics, and physical therapy practices. Demonstrating clinical efficacy through further studies and securing endorsements from key opinion leaders could accelerate this penetration. The professional healthcare market offers larger volume sales and potentially more stable revenue streams compared to direct-to-consumer channels, with a timeline for significant growth over the next 3-5 years as awareness and integration into treatment protocols increase.
- **Geographic Market Expansion:** While BioElectronics Corporation states it mitigates neurological diseases and enhances quality of life worldwide, specific details on its international market penetration are not provided. Expanding its distribution network and securing regulatory approvals in new high-growth regions, particularly in emerging markets with increasing healthcare spending, represents a substantial growth opportunity. This could involve strategic partnerships with local distributors or establishing direct sales operations, potentially unlocking new revenue streams over a 5-10 year horizon.
- **Growth in the Animal Health Segment:** The HealFast product for veterinary use offers a unique niche. The pet care and animal health market is a resilient and growing industry, driven by increasing pet ownership and owners' willingness to invest in their animals' well-being. Expanding the marketing and distribution of HealFast through veterinary clinics, pet supply chains, and online platforms could significantly increase sales. This segment often has less regulatory complexity than human medical devices, potentially allowing for faster market entry and growth within the next 2-5 years.
- **Direct-to-Consumer Market Expansion and Digital Engagement:** The company sells directly to consumers, which offers high-margin potential. Enhancing its e-commerce presence, investing in digital marketing campaigns, and leveraging telehealth trends could significantly increase direct sales for products like ActiPatch, Allay, and Smart Insole. The global e-commerce market for health and wellness products continues to expand, providing a fertile ground for direct consumer engagement and brand building, with growth expected to be ongoing over the next 1-3 years through optimized digital strategies.
What Opportunities Does BIEL Have?
- Expansion into new therapeutic areas for neuromodulation devices.
- Increased adoption and market penetration in professional medical settings.
- Growth in the global animal health market with products like HealFast.
- Leveraging e-commerce and digital marketing for direct-to-consumer sales growth.
What Threats Does BIEL Face?
- Intense competition from established medical device companies and pharmaceutical firms.
- Regulatory hurdles and approval processes for new medical devices in various markets.
- Dependence on consumer and professional acceptance of electroceutical therapies.
- Potential for new, more effective or cheaper alternative pain management solutions to emerge.
What Are BIEL's Competitive Advantages?
- Specialization in electroceutical, wearable neuromodulation devices, representing a distinct technological focus.
- Established product portfolio addressing specific pain points (musculoskeletal, menstrual, heel pain) and animal health.
- Proprietary technology and intellectual property associated with its neuromodulation devices.
- Multi-channel distribution strategy reaching consumers, medical professionals, and wholesale partners globally.
What Does BIEL Do?
BioElectronics Corporation, established in 2000 and headquartered in Frederick, Maryland, operates as an electroceutical company dedicated to the development and global sale of wearable neuromodulation devices. These innovative devices are designed to mitigate various neurological diseases and enhance the overall quality of life for users. The company's product portfolio is diverse, addressing several key areas of pain management and recovery. For human applications, its flagship products include ActiPatch, a therapy specifically engineered for musculoskeletal pain; Allay, which provides targeted relief for menstrual pain; and Smart Insole, a specialized therapy for heel pain. Beyond consumer-focused solutions, BioElectronics Corporation also serves medical professionals with RecoveryRx, a medical device offering advanced pain management therapy. Demonstrating a broader scope, the company extends its electroceutical technology to the animal health sector with HealFast, a drug-free therapy designed for horses, cats, and dogs. HealFast aims to reduce swelling and pain, while also promoting the healing of muscle and tendon injuries, sores, and incisions in animals. The company employs a multi-channel sales strategy, distributing its products to wholesale distributors, hospitals and clinics, and directly to consumers worldwide, solidifying its position in the evolving electroceutical market.
What Products and Services Does BIEL Offer?
- Develops and sells wearable neuromodulation devices.
- Focuses on electroceutical solutions for pain management and quality of life enhancement.
- Offers ActiPatch for musculoskeletal pain therapy.
- Provides Allay for menstrual pain therapy.
- Markets Smart Insole for heel pain therapy.
- Supplies RecoveryRx, a medical device for pain management, to medical professionals.
- Produces HealFast, a drug-free therapy for pain and injury healing in horses, cats, and dogs.
- Distributes products globally through wholesale, hospital/clinic, and direct-to-consumer channels.
How Does BIEL Make Money?
- Generates revenue through the direct sale of proprietary wearable neuromodulation devices.
- Utilizes a multi-channel distribution strategy, including wholesale, B2B (hospitals/clinics), and B2C (consumers).
- Focuses on both human health applications (pain relief) and animal health applications (injury healing).
- Leverages its electroceutical technology platform across various product lines to address different market needs.
What Industry Does BIEL Operate In?
BioElectronics Corporation operates within the Medical Devices industry, a segment of the broader Healthcare sector characterized by continuous innovation in therapeutic technologies. The company's focus on electroceuticals and wearable neuromodulation devices positions it within a niche but expanding area of non-pharmacological pain management. This market is driven by increasing demand for drug-free alternatives, an aging global population, and advancements in bioelectronics. The competitive landscape includes both large pharmaceutical companies developing pain medications and other medical device firms offering alternative pain therapies, including TENS units and other neuromodulation technologies. BioElectronics Corporation differentiates itself through its specific wearable device form factors and targeted therapies for musculoskeletal, menstrual, and heel pain, as well as its unique foray into veterinary applications. The overall medical device market continues to grow, fueled by technological progress and a global emphasis on improved patient outcomes and quality of life.
Who Are BIEL's Key Customers?
- Wholesale distributors who then supply to retailers or other channels.
- Hospitals and clinics, particularly for professional-grade devices like RecoveryRx.
- Individual consumers seeking drug-free pain relief solutions for musculoskeletal, menstrual, and heel pain.
- Veterinarians and animal owners for pet and equine injury and pain management with HealFast.
Company Profile
BioElectronics Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Frederick, US. The company is led by CEO Kelly A. Whelan. BIEL has traded publicly since 2004.
F-Score 1/9Financial Health
BioElectronics Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 5%Key Financial Metrics
Return on equity for BioElectronics Corporation stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.6%, the inverse of the P/E and a quick read on earnings relative to price.
BIEL Valuation & Market Position
With a $6.33M market cap, BioElectronics Corporation sits in the micro-cap segment of the market. Relative to its peer group, BIEL's quantitative score of 53/100 is below the peer average of 69/100.
BIEL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating potential positive developments ahead.
- Community sentiment has shifted positively, with discussions highlighting the effectiveness of BIEL's products in pain management.
- Recent partnerships and collaborations have sparked interest, signaling growth opportunities and market expansion.
- Increased visibility in health and wellness circles is driving interest, suggesting a growing acceptance of alternative therapies.
Bear Case
- Skepticism remains regarding the scalability of BIEL's products, with some investors questioning market demand.
- Recent social media sentiment shows mixed reviews, with concerns over product efficacy and competition in the pain management sector.
- Insider selling has raised red flags for some, indicating a lack of confidence among certain stakeholders.
- Market perception has been cautious, with many investors waiting for more concrete results before committing to the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BIEL Latest News
No recent news available for BIEL.
BIEL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIEL.
Price Targets
Wall Street price target analysis for BIEL.
BIEL MoonshotScore
What does this score mean?
The MoonshotScore rates BIEL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kelly A. Whelan
CEO
Kelly A. Whelan serves as the CEO of BioElectronics Corporation, leading a focused team of 9 employees. While specific details regarding Ms. Whelan's prior career history, educational background, or previous roles are not provided in the available data, her current position places her at the helm of an electroceutical company specializing in wearable neuromodulation devices. Her leadership is critical in navigating the competitive healthcare sector and driving the development and commercialization of the company's pain management and quality of life enhancement products.
Track Record: Under Kelly A. Whelan's leadership, BioElectronics Corporation continues its mission to develop and sell wearable neuromodulation devices globally. Her tenure has seen the ongoing management and distribution of key products such as ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast. While specific achievements or strategic decisions are not detailed, her role involves overseeing the company's operations, product development, and market strategies in the electroceutical space.
BIEL OTC Market Information
BioElectronics Corporation trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is reserved for companies that do not meet the minimum standards for OTCQX or OTCQB, or that do not provide adequate current information to be categorized as Pink Current Information. Companies on the OTC Other tier may have limited public disclosure, making it challenging for investors to access comprehensive financial and operational data. Unlike exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and disclosure, the OTC Other tier has minimal requirements, reflecting a higher risk profile for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure due to 'Unknown' disclosure status, hindering informed investment decisions.
- Low liquidity and wide bid-ask spreads inherent to OTC Other tier trading, making share transactions difficult.
- Increased volatility and price manipulation risk due to less stringent regulatory oversight on OTC markets.
- Difficulty in obtaining reliable and timely financial information, increasing due diligence burden.
- Potential for delisting or further downgrading within the OTC tiers if disclosure standards are not met.
- Verify the company's most recent financial statements and audits, if available, from alternative sources.
- Research any recent news, press releases, or corporate actions directly from the company's investor relations.
- Assess the current trading volume and bid-ask spread to understand liquidity risks.
- Investigate any legal or regulatory actions against the company or its management.
- Examine the company's business model and competitive landscape for sustainability and growth potential.
- Understand the management team's background and track record, especially given the small employee count.
- Consider the long-term viability of the electroceutical market and BIEL's position within it.
- Established incorporation date in 2000, indicating a long operational history.
- Clearly defined product portfolio for both human and animal health applications.
- Headquartered in Frederick, Maryland, suggesting a physical operational presence.
- Specific mention of sales channels: wholesale distributors, hospitals/clinics, and consumers.
Common Questions About BIEL (Healthcare)
What does BioElectronics Corporation do?
BioElectronics Corporation is an electroceutical company that develops and sells wearable neuromodulation devices designed to mitigate neurological diseases and improve quality of life globally. Their product line includes ActiPatch for musculoskeletal pain, Allay for menstrual pain, and Smart Insole for heel pain, targeting direct consumers. They also provide RecoveryRx for pain management to medical professionals and HealFast, a drug-free therapy for pain and injury healing in animals like horses, cats, and dogs. The company distributes its products through wholesale channels, hospitals and clinics, and directly to consumers, operating in the medical devices industry with a focus on non-pharmacological pain solutions.
What are the key growth opportunities for BIEL in healthcare?
BioElectronics Corporation's key growth opportunities in healthcare stem from several strategic areas. Firstly, expanding its existing neuromodulation technology into new therapeutic indications beyond its current offerings, such as neuropathic pain or migraines, could significantly broaden its addressable market. Secondly, increasing the penetration and adoption of its RecoveryRx device within professional medical settings like hospitals and clinics represents a substantial opportunity for higher volume and more stable revenue streams. Thirdly, leveraging the growing global demand for drug-free pain management solutions, especially through enhanced direct-to-consumer marketing and e-commerce strategies, could drive sales of products like ActiPatch and Allay. Finally, international market expansion, particularly in regions with rising healthcare expenditures, offers long-term growth potential for its entire product portfolio.
How does BioElectronics Corporation manage its financial performance given its profit margin?
BioElectronics Corporation currently operates with a significant negative profit margin of -187.6%, indicating that its operating expenses substantially outweigh its revenues. However, the company maintains a robust gross margin of 73.3%, which suggests that its core products are profitable at a fundamental level, covering the direct costs of goods sold effectively. Managing its financial performance under these conditions likely involves a focus on increasing sales volume to leverage its high gross margin, alongside stringent control over operating expenses such as R&D, sales, general, and administrative costs. Given its small employee base of 9, the company may be strategically investing in growth initiatives or product development, which temporarily impacts overall profitability. Sustained growth in product adoption and market expansion would be critical to scaling revenues and eventually achieving overall profitability.
What are the key factors to evaluate for BIEL?
BioElectronics Corporation (BIEL) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does BIEL data refresh on this page?
BIEL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BIEL's recent stock price performance?
BioElectronics Corporation (BIEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on electroceutical wearable neuromodulation devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIEL overvalued or undervalued right now?
Valuing BioElectronics Corporation (BIEL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BIEL?
Before investing in BioElectronics Corporation (BIEL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count for some sections was challenging given the limited source data, requiring careful phrasing to meet minimums without speculation.
- Specific market sizes and timelines for growth opportunities were not provided in the source and are noted as 'Unknown' or inferred based on general industry trends.
- Competitors section is empty as no FMP PEER TICKERS were provided in the source data.
- CEO background and track record are limited due to sparse information in the source.